(Source: Enanta Pharmaceuticals Inc) New once-daily, extended-release co-formulation contains the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection Paritaprevir is Enanta's lead protease inhibitor and one of the three direct-acting antivirals in VIEKIRA XR WATERTOWN, Mass.--(BUSINESS WIRE)--Jul. 25, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AbbVie's New Drug Application (NDA)...
↧